SORTAG

Serial Number 79379532
602

Registration Progress

Application Filed
Aug 25, 2023
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

SORTAG

Basic Information

Serial Number
79379532
Filing Date
August 25, 2023
Abandonment Date
September 30, 2024
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Oct 10, 2024
Classes
005 042 044

Rights Holder

VectorY B.V.

99
Address
Science Park 408
NL-1098 XH Amsterdam
NL

Ownership History

VectorY B.V.

Original Applicant
99
NL

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

14 events
Date Code Type Description Documents
Mar 14, 2025 OPNX P NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Loading...
Feb 27, 2025 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Feb 27, 2025 OPNR P NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Loading...
Oct 10, 2024 MAB2 O ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Loading...
Oct 10, 2024 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Apr 24, 2024 RFNT P REFUSAL PROCESSED BY IB Loading...
Mar 29, 2024 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Mar 28, 2024 RFRR P REFUSAL PROCESSED BY MPU Loading...
Mar 10, 2024 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Mar 9, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 6, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 3, 2023 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Sep 29, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 28, 2023 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Viral systems, gene therapy systems, nucleic acid delivery systems, namely, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, vaccines, prophylaxis products and other pharmaceutical products for use in nucleic acid-based therapy, gene therapy and cell therapy
Class 042
Research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; research and product development in the field of pharmaceutics
Class 044
Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; consultancy in the field of pharmaceutics

Additional Information

Pseudo Mark
SORT TAG

Classification

International Classes
005 042 044